« Previous
Next »
Journal of Oral and Maxillofacial Surgery
Volume 68, Issue 2
, Pages
243-253
, February 2010
Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure
To access this article, please choose from the options below
This study was funded by the US Food and Drug Administration (HHSF223200510008C), the National Institute of Child Health and Human Development at the National Institutes of Health (K12 HD052163), and the Kaiser Permanente Community Benefit Program; a portion of this study was also supported by the National Center for Research Resources at the National Institutes of Health (UCSF-CTSI UL1 RR024131).
J. Lo previously received research funding from Novartis; D. Martin previously owned stock in Merck & Company, Incorporated; a household family member of N. Gordon previously owned stock in Novartis Pharmaceuticals; a nonhousehold family member of F. O'Ryan is employed by Roche Laboratories; A. Go previously received research funding from Amgen and currently receives research funding from GlaxoSmithKline.
The contents of this publication are solely the responsibility of the authors and do not represent the official views of the Food and Drug Administration or the National Institutes of Health.
PII: S0278-2391(09)00441-8
doi: 10.1016/j.joms.2009.03.050
© 2010 American Association of Oral and Maxillofacial Surgeons. All rights reserved.
« Previous
Next »
Journal of Oral and Maxillofacial Surgery
Volume 68, Issue 2
, Pages
243-253
, February 2010
